Nina Capital’s Post

NEWS Methinks AI expands stroke detection solution into contrast imaging with second US FDA clearance Methinks has received FDA 510(k) clearance for Methinks computed tomography angiography (CTA) Stroke, an artificial intelligence (AI)-based software solution intended to accurately detect suspected large vessel occlusions (LVOs) using CTA scans. This marks the company’s second FDA 510(k) clearance of 2025 after its non-contrast computed tomography (NCCT) Stroke software gained approval from the US regulator in July. “We’re proud to have achieved our second US FDA clearance this year, a milestone that reflects the strength and maturity of our regulatory team and processes,” said Methinks chief executive officer (CEO) Pau Rodríguez. “This accomplishment demonstrates our ability to deliver advanced, accessible stroke care solutions across US hospitals.” Congrats for this big milestone Pau and team! https://lnkd.in/d7wXuAf9 #wearenina

To view or add a comment, sign in

Explore content categories